Skip to Content

McKesson Corp MCK Stock Quote

| Rating as of

Morningstar‘s Stock Analysis MCK

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Raising McKesson FVE to $298 Following European Divestment and COVID-19 Contract Extensions

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

We are raising our fair value estimate on narrow-moat McKesson to $298 from $235 per share after we did a deeper dive into the industry and adjusted for strong first-quarter performance as well as revised fiscal year guidance. The main change in our outlook pertains to operating expenses involving labor, shipping, and facility costs. In the first quarter, the firm completed a large part of its program to permanently divest of its European distribution business in the international segment. The sale significantly reduced operating expenses as a percentage of sales year over year despite higher revenue. Though revenue was propped up by vaccine and test kit distribution contracts with the U.S. government, these contracts were extended into early- to mid-2023. The extension should smooth out the top-line impact of the European divestitures. A smaller factor in our revision is the relatively high-margin primary care business contributing to an improved sales mix. While we left our gross margin forecast stable, we lowered our five-year forecast for operating costs as a percentage of sales by 30 basis points to accommodate these trends.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics MCK

Company Profile MCK

Business Description

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

6555 State Highway 161
Irving, TX, 75039
T +1 972 446-4800
Industry Medical Distribution
Most Recent Earnings Jun 30, 2022
Fiscal Year End Mar 31, 2023
Employees 75,000

Related News MCK